India's bio-economy is on course to become a $1 trillion powerhouse by 2047, positioning the country among the top three global bio-economies, Union Minister Dr Jitendra Singh declared on Friday, April 25 at an international conference hosted by IIT Roorkee, Uttarakhand. The minister's remarks signal a decisive shift in India's economic identity — from a services-led nation to a biology-and-innovation-driven global force. This projection comes as India accelerates investments across biotechnology, deep-tech, and quantum research.

India's Bio-Economy: From $10 Billion to $165 Billion in a Decade

Dr Jitendra Singh highlighted one of the most striking economic transformations in recent Indian history. India's bio-economy grew from just $10 billion in 2014 to over $165 billion today, clocking a compound annual growth rate of nearly 18 per cent. The government has set an interim target of $300 billion by 2030, before the ultimate goal of $1 trillion by 2047 — coinciding with India's centenary of independence.

Equally remarkable is the explosion in the startup ecosystem. The number of biotech startups surged from approximately 50 in 2014 to over 11,000 today, according to the Ministry of Science and Technology. This 220-fold increase reflects not just policy support but a generational shift in how young Indians are channelling scientific ambition into enterprise.

National Quantum Mission and Global Innovation Index Gains

The minister noted that India's technological ambitions extend well beyond biology. The National Quantum Mission has achieved key milestones ahead of schedule, placing India in the top ranks globally in critical technology domains. He described India's trajectory as advancing toward full-spectrum technological capability — from gene to qubit, from ocean depths to outer space.

India's Global Innovation Index ranking improved dramatically from 81 to 39 over recent years, a 42-place leap that reflects sustained institutional investment. Research and development expenditure has more than doubled over the past decade, signalling that science and innovation have become non-negotiable national priorities rather than aspirational footnotes in budget speeches.

Key Scientific Breakthroughs Cited by the Minister

Dr Jitendra Singh presented a series of landmark scientific advances that underpin this optimism. These include significant progress under the Genome India initiative, the development of indigenous CAR-T cell therapy, the creation of mRNA vaccine platforms, and the successful development of India's first indigenously produced antibiotic. Each of these represents not just a scientific milestone but a potential export and public health asset.

He also drew attention to the expansion of nuclear medicine facilities aimed at delivering affordable cancer care to a broader population — a critical intervention given that India accounts for a significant share of global cancer burden. Progress in deep ocean exploration through the Samudrayaan mission was also highlighted as part of India's push into frontier science.

Funding Architecture: ANRF and the RDI Fund

Backing these ambitions is a robust financial architecture. The minister referenced the Anusandhan National Research Foundation (ANRF), endowed with a corpus of Rs 50,000 crore, alongside the Research, Development and Innovation (RDI) Fund worth Rs 1 lakh crore. Both instruments are designed to provide long-term, low-cost financing for deep-tech innovation, addressing a historically chronic gap in India's R&D funding landscape.

This is a structural departure from India's past approach, where public R&D spending as a percentage of GDP consistently lagged behind China, South Korea, and Israel. Critics have long argued that India's innovation potential was throttled by underfunding — the ANRF and RDI Fund are direct policy responses to that critique.

Why This Matters: The Bigger Picture

India's bio-economy ambitions arrive at a pivotal geopolitical moment. As global supply chains for pharmaceuticals, agricultural biotech, and medical devices are being restructured away from overdependence on China, India is positioning itself as the credible alternative. The 21st century as India's century, as Dr Singh framed it, is not merely rhetorical — it is backed by a convergence of demographic dividend, policy reform, and institutional capacity-building that few nations can replicate at this scale.

The next critical milestones to watch include India's performance in the 2025 Global Innovation Index, progress updates on the National Quantum Mission, and the government's mid-term review of the $300 billion bio-economy target by 2030. How India translates these projections into ground-level outcomes — particularly in rural healthcare, agricultural productivity, and export competitiveness — will determine whether 2047 ambitions remain aspirational or become transformational.